0.00
0.00%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Windtree Therapeutics
Its shares trade under the ticker WINT. It has been listed since 9 August 1995. In the fiscal year to 31 December 2019, it reported revenue of $198,000 and a net loss of $27.5m. At that date it held total assets of $119.0m and shareholders' equity of $74.9m.
Windtree Therapeutics, Inc. engages in the manufacture and development of products for infants and respiratory diseases. The company is headquartered in Warrington, Pennsylvania. The firm is focused on developing KL4 surfactant therapies for respiratory diseases and other potential applications. The firm operates through the research and development of products focused on surfactant therapies for respiratory disorders and diseases, and the manufacture and commercial sales of approved products segment. The firm's technology platform includes a synthetic, peptide-containing surfactant (KL4 surfactant) that is structurally similar to endogenous pulmonary surfactant, and drug delivery technologies being developed to enable non-invasive administration of aerosolized KL4 surfactant. The firm's core development program, AEROSURF (lucinactant for inhalation), is focused on improving the management of respiratory distress syndrome (RDS) in premature infants, a respiratory condition that can result in long-term respiratory problems, developmental delay and death.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 9 Aug 1995
- Employees
- 14
- Website
- windtreetx.com ↗
- Head office
- 2600 KELLY ROAD, WARRINGTON, PA, 18976
- Incorporated in
- DE
- Classification
- Biological Products, (No Diagnostic Substances)
- Filer status
- Non-accelerated filer<br>Smaller reporting company
Leadership
Pay as last reported
- Dr. Mark StrobeckIndependent Chairman of the Board$56,215
- Mr. Jed LatkinPresident, Chief Executive Officer, Director, since 2024$69,021
- Mr. Andrew KucharchukIndependent Director
- Ms. Saundra PelletierIndependent Director$23,372
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Windtree Therapeutics focuses on KL4 surfactant therapies for respiratory diseases with 31 employees.
- AEROSURF (lucinactant for inhalation) targets respiratory distress syndrome in premature infants.
- Windtree's synthetic peptide-containing surfactant platform is structurally similar to endogenous pulmonary surfactant.
Weaknesses
- Windtree Therapeutics has only 14 employees as per the facts provided.
- The company is headquartered in Warrington, Pennsylvania, a small city.
- Windtree's business is limited to respiratory disease therapies with no other segments.
Opportunities
- Windtree's AEROSURF program could expand to treat other respiratory disorders beyond RDS.
- The company's synthetic surfactant technology may be applied to new drug delivery systems.
- Windtree could explore partnerships for commercial sales of approved products.
Threats
- Windtree faces competition from other biotechnology firms in respiratory disease treatments.
- The company's focus on a single product line poses a risk if development fails.
- Regulatory approval delays could impact Windtree's AEROSURF program timeline.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.